rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2019-191-196rsp-2705Research ArticleПРОГРАММА НЕПРЕРЫВНОГО ПОСЛЕДИПЛОМНОГО ОБРАЗОВАНИЯ ВРАЧЕЙPOSTGRADUATE PROGRAM OF CONTINUING MEDICAL EDUCATIONВедение пациентов с системной красной волчанкой в реальной клинической практикеManagement of patients with systemic lupus erythematosus in real clinical practiceАсееваЕ. А.AseevaE. A.

ведущий научный сотрудник лаборатории интенсивных методов лечения, канд. мед. наук

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow, 115522

eaasseeva@mail.ruСоловьевС. К.SolovievS. K.

профессор, зав. лабораторией интенсивных методов лечения, докт. мед. наук

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow, 115522

ПопковаТ. В.PopkovaT. V.

зав. лабораторией системных ревматических  заболеваний, докт. мед. наук

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow, 115522

НикишинаН. Ю.NikishinaN. Yu.

научный сотрудник лаборатории интенсивных методов лечения, канд. мед. наук

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow, 115522

МеснянкинаА. А.MesnyankinaA. A.

младший научный сотрудник лаборатории интенсивных методов лечения, канд. мед. наук

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow, 115522

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation201914052019572191196Copyright © Асеева Е.А., Соловьев С.К., Попкова Т.В., Никишина Н.Ю., Меснянкина А.А., 20192019Асеева Е.А., Соловьев С.К., Попкова Т.В., Никишина Н.Ю., Меснянкина А.А.Aseeva E.A., Soloviev S.K., Popkova T.V., Nikishina N.Y., Mesnyankina A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2705

Представлены рекомендации по ведению пациентов с системной красной волчанкой (СКВ) в реальной клинической практике с учетом характера течения, активности, повреждений, с использованием валидированных индексов. Дана характеристика терапевтических схем, рассмотрены особенности мониторинга пациентов с СКВ.

Recommendations for the management of patients with systemic lupus erythematosus (SLE) in real clinical practice are presented. They take into account the course, activity, damage, and consider assessment of these parameters with validated indices. The characteristic of therapeutic schemes is given, features of monitoring of patients with SLE are considered.

системная красная волчанкаактивностьтечениетерапиямониторингsystemic lupus erythematosusactivitycoursetherapymonitoringReferencesНасонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017.Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2017 (In Russ.).Lahita RG, Tsokos G, Buyon J, Koike T, eds. Systemic lupus erythematosus. 5 th ed. London: Elsevier; 2011.Lahita RG, Tsokos G, Buyon J, Koike T, eds. Systemic lupus erythematosus. 5 th ed. London: Elsevier; 2011.Dai C, Deng Y, Quinlan A, et al. Genetics of systemic lupus erythematosus: immune responses and end organ resistance to damage. Curr Opin Immunol. 2014 Dec;31:87-96. doi: 10.1016/j.coi.2014.10.004. Epub 2014 Oct 25.Dai C, Deng Y, Quinlan A, et al. Genetics of systemic lupus erythematosus: immune responses and end organ resistance to damage. Curr Opin Immunol. 2014 Dec;31:87-96. doi: 10.1016/j.coi.2014.10.004. Epub 2014 Oct 25.Odendahl M, Jacobi A, Hansen A, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol. 2000 Nov 15;165(10):5970-9. doi: 10.4049/jimmunol.165.10.5970Odendahl M, Jacobi A, Hansen A, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol. 2000 Nov 15;165(10):5970-9. doi: 10.4049/jimmunol.165.10.5970Cervera R, Khamashta MA, Hughes GR. The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe. Lupus. 2009 Sep;18(10):869-74. doi: 10.1177/0961203309106831Cervera R, Khamashta MA, Hughes GR. The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe. Lupus. 2009 Sep;18(10):869-74. doi: 10.1177/0961203309106831Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi: 10.1002/art.1780400928Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi: 10.1002/art.1780400928Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677-86. doi: 10.1002/art.34473Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677-86. doi: 10.1002/art.34473Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288-91.Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288-91.Gladman DD, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus. Arthritis Rheum. 1996 Mar;39(3):363-9. doi: 10.1002/art.1780390303Gladman DD, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus. Arthritis Rheum. 1996 Mar;39(3):363-9. doi: 10.1002/art.1780390303Tunnicliffe DJ, Singh-Grewal D, Kim S, et al. Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus: A Systematic Review of Clinical Practice Guidelines. Arthritis Care Res (Hoboken). 2015 Oct;67(10):1440-52. doi: 10.1002/acr.22591Tunnicliffe DJ, Singh-Grewal D, Kim S, et al. Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus: A Systematic Review of Clinical Practice Guidelines. Arthritis Care Res (Hoboken). 2015 Oct;67(10):1440-52. doi: 10.1002/acr.22591Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65:521-30. doi: 10.1111/j.1523-1755.2004.00443.xWeening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65:521-30. doi: 10.1111/j.1523-1755.2004.00443.xWilhelmus S, Alpers CE, Cook HT, et al. The Revisited Classification of GN in SLE at 10 Years: Time to Re-Evaluate Histopathologic Lesions. J Am Soc Nephrol. 2015;26(12):2938-46. doi: 10.1681/ASN.2015040384Wilhelmus S, Alpers CE, Cook HT, et al. The Revisited Classification of GN in SLE at 10 Years: Time to Re-Evaluate Histopathologic Lesions. J Am Soc Nephrol. 2015;26(12):2938-46. doi: 10.1681/ASN.2015040384Van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014 Jun;73(6):958-67. doi: 10.1136/annrheumdis-2013-205139. Epub 2014 Apr 16.Van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014 Jun;73(6):958-67. doi: 10.1136/annrheumdis-2013-205139. Epub 2014 Apr 16.Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.xMiyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.xMosca M, Tani C, Aringer M, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010;69:1269-74. doi: 10.1136/ard.2009.117200Mosca M, Tani C, Aringer M, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010;69:1269-74. doi: 10.1136/ard.2009.117200Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012;64:797-808. doi: 10.1002/acr.21664Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012;64:797-808. doi: 10.1002/acr.21664Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal AssociationEuropean Dialysis and Transplant Association (EULAR/ERAEDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012 Nov;71(11):1771-82. doi: 10.1136/annrheumdis-2012-201940Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal AssociationEuropean Dialysis and Transplant Association (EULAR/ERAEDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012 Nov;71(11):1771-82. doi: 10.1136/annrheumdis-2012-201940Pamfil C, Fanouriakis A, Damian L, et al. EULAR recommendations for neuropsychiatric systemic lupus erythematosus vs usual care: results from two European centres. Rheumatology (Oxford). 2015 Jul;54(7):1270-8. doi: 10.1093/rheumatology/keu482Pamfil C, Fanouriakis A, Damian L, et al. EULAR recommendations for neuropsychiatric systemic lupus erythematosus vs usual care: results from two European centres. Rheumatology (Oxford). 2015 Jul;54(7):1270-8. doi: 10.1093/rheumatology/keu482Wilhelmus S, Bajema IM, Bertsias GK, et al. Lupus nephritis management guidelines compared. Nephrol Dial Transplant. 2016 Jun;31(6):904-13. doi: 10.1093/ndt/gfv102Wilhelmus S, Bajema IM, Bertsias GK, et al. Lupus nephritis management guidelines compared. Nephrol Dial Transplant. 2016 Jun;31(6):904-13. doi: 10.1093/ndt/gfv102Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012 Jun;64(6):797-808. doi: 10.1002/acr.21664Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012 Jun;64(6):797-808. doi: 10.1002/acr.21664Keeling SO, Alabdurubalnabi Z, Avina-Zubieta A, et al. Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. J Rheumatol. 2018 Oct;45(10):1426-39. doi: 10.3899/jrheum.171459Keeling SO, Alabdurubalnabi Z, Avina-Zubieta A, et al. Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. J Rheumatol. 2018 Oct;45(10):1426-39. doi: 10.3899/jrheum.171459Barile-Fabris L, Hernandez-Cabrera MF, BarraganGarfias JA. Vasculitis in systemic lupus erythematosus. Curr Rheumatol Rep. 2014;16(9):440. doi: 10.1007/s11926-014-0440-9Barile-Fabris L, Hernandez-Cabrera MF, BarraganGarfias JA. Vasculitis in systemic lupus erythematosus. Curr Rheumatol Rep. 2014;16(9):440. doi: 10.1007/s11926-014-0440-9Wallace DJ, Navarra S, Petri MA, et al. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus. 2013 Feb;22(2):144-54. doi: 10.1177/0961203312469259Wallace DJ, Navarra S, Petri MA, et al. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus. 2013 Feb;22(2):144-54. doi: 10.1177/0961203312469259Ginzler EM, Wallace DJ, Merrill JT, et al. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol. 2014 Feb;41(2):300-9. doi: 10.3899/jrheum.121368Ginzler EM, Wallace DJ, Merrill JT, et al. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol. 2014 Feb;41(2):300-9. doi: 10.3899/jrheum.121368Mok CC. Current role of rituximab in systemic lupus erythematosus. Int J Rheum Dis. 2015 Feb;18(2):154-63. doi: 10.1111/1756-185X.12463Mok CC. Current role of rituximab in systemic lupus erythematosus. Int J Rheum Dis. 2015 Feb;18(2):154-63. doi: 10.1111/1756-185X.12463Chi-Ching Chang, Yu-Sheng Chang, Wei-Sheng Chen, et al. Effects of annual influenza vaccination on morbidity and mortality in patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study. Sci Rep. 2016;6:37817. doi: 10.1038/srep37817Chi-Ching Chang, Yu-Sheng Chang, Wei-Sheng Chen, et al. Effects of annual influenza vaccination on morbidity and mortality in patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study. Sci Rep. 2016;6:37817. doi: 10.1038/srep37817Yun H, Yang S, Chen L, et al. Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination. Arthritis Rheum. 2016 Sep;68(9):2328-37. doi: 10.1002/art.39670Yun H, Yang S, Chen L, et al. Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination. Arthritis Rheum. 2016 Sep;68(9):2328-37. doi: 10.1002/art.39670Белов БС, Соловьев СК, Тарасова ГМ, Асеева ЕА. Вакцинация у больных системной красной волчанкой: результаты и перспективы. Научно-практическая ревматология. 2018;56(3):373-9. doi: 10.14412/1995-4484-2018-373-379Belov BS, Solovyev SK, Tarasova GM, Aseeva EA. Vaccination in patients with systemic lupus erythematosus: results and prospects. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(3):373-9 (In Russ.). doi: 10.14412/1995-4484-2018-373-379Kronbichler A, Brezina B, Quintana LF, Jayne DR. Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: A systematic review. Autoimmun Rev. 2016 Jan;15(1):38-49. doi: 10.1016/j.autrev.2015.08.010Kronbichler A, Brezina B, Quintana LF, Jayne DR. Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: A systematic review. Autoimmun Rev. 2016 Jan;15(1):38-49. doi: 10.1016/j.autrev.2015.08.010Smyth A, Oliveira GH, Lahr BD, et al. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol. 2010 Nov;5(11):2060-8. doi: 10.2215/CJN.00240110Smyth A, Oliveira GH, Lahr BD, et al. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol. 2010 Nov;5(11):2060-8. doi: 10.2215/CJN.00240110Ruiz-Irastorza G, Khamashta MA. Lupus and pregnancy: ten questions and some answers. Lupus. 2008;17(5):416-20. doi: 10.1177/0961203308090027Ruiz-Irastorza G, Khamashta MA. Lupus and pregnancy: ten questions and some answers. Lupus. 2008;17(5):416-20. doi: 10.1177/0961203308090027Ostensen M, Khamashta M, Lockshin M, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther. 2006;8(3):209. doi: 10.1186/ar1957Ostensen M, Khamashta M, Lockshin M, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther. 2006;8(3):209. doi: 10.1186/ar1957Кошелева НМ. Планирование беременности и наблюдение за беременными с ревматическими заболеваниями. В кн.: Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. С. 371-93.Kosheleva NM. Planning for pregnancy and monitoring pregnant women with rheumatic diseases. In: Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2017. P. 371-93 (In Russ.).

The authors declare that there are no conflicts of interest present.